A phase II, multicenter, randomized, double-blind, placebo-controlled, ascending dose, dose ranging study to evaluate up to three doses of R935788 [R-788, fostamatinib; Rigel] in rheumatoid arthritis patients failing to respond to methotrexate.

Trial Profile

A phase II, multicenter, randomized, double-blind, placebo-controlled, ascending dose, dose ranging study to evaluate up to three doses of R935788 [R-788, fostamatinib; Rigel] in rheumatoid arthritis patients failing to respond to methotrexate.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 May 2009

At a glance

  • Drugs Fostamatinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms TASKI-1
  • Sponsors Rigel Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Nov 2008 Results have been published in Arthritis and Rheumatism according to a Rigel media release.
    • 29 Oct 2008 Results were presented at the American College of Rheumatology meeting in Oct 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top